These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 19287288)

  • 21. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study.
    Chan WM; Lai TY; Liu DT; Lam DS
    Ophthalmology; 2007 Dec; 114(12):2190-6. PubMed ID: 17599414
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intravitreal bevacizumab in the treatment of neovascular age-related macular degeneration, 6- and 9-month results.
    Cleary CA; Jungkim S; Ravikumar K; Kelliher C; Acheson RW; Hickey-Dwyer M
    Eye (Lond); 2008 Jan; 22(1):82-6. PubMed ID: 17891059
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
    Avery RL; Pieramici DJ; Rabena MD; Castellarin AA; Nasir MA; Giust MJ
    Ophthalmology; 2006 Mar; 113(3):363-372.e5. PubMed ID: 16458968
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration in treatment-naive patients.
    Pedersen KB; Sjølie AK; Møller F
    Acta Ophthalmol; 2009 Nov; 87(7):714-9. PubMed ID: 19094171
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Effectivity and safety of bevacizumab intravitreal injections for exudative age-related macular degeneration treatment--6 months observations].
    Małgorzata F
    Klin Oczna; 2010; 112(7-9):213-6. PubMed ID: 21121123
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of 1.25 MG versus 2.5 MG intravitreal bevacizumab for diabetic macular edema: six-month results of a randomized controlled trial.
    Lam DS; Lai TY; Lee VY; Chan CK; Liu DT; Mohamed S; Li CL
    Retina; 2009 Mar; 29(3):292-9. PubMed ID: 19287286
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intravitreal bevacizumab therapy on an as-per-needed basis in subfoveal choroidal neovascularization secondary to pathological myopia: 2-year outcomes of a prospective case series.
    Iacono P; Parodi MB; Papayannis A; Kontadakis S; Sheth S; Bandello F
    Retina; 2011 Oct; 31(9):1841-7. PubMed ID: 21775926
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intravitreal bevacizumab combined with photodynamic therapy for the treatment of occult choroidal neovascularization associated with serous pigment epithelium detachment in age-related macular degeneration.
    Ladas ID; Kotsolis AI; Papakostas TD; Rouvas AA; Karagiannis DA; Vergados I
    Retina; 2007 Sep; 27(7):891-6. PubMed ID: 17891013
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative study of intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) in the treatment of neovascular age-related macular degeneration.
    Landa G; Amde W; Doshi V; Ali A; McGevna L; Gentile RC; Muldoon TO; Walsh JB; Rosen RB
    Ophthalmologica; 2009; 223(6):370-5. PubMed ID: 19590252
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of intravitreal bevacizumab (Avastin) in neovascular age-related macular degeneration using a treatment regimen based on optical coherence tomography: 6- and 12-month results.
    Leydolt C; Michels S; Prager F; Garhoefer G; Georgopoulos M; Polak K; Schmidt-Erfurth U
    Acta Ophthalmol; 2010 Aug; 88(5):594-600. PubMed ID: 19485959
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
    Ding X; Li J; Hu X; Yu S; Pan J; Tang S
    Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of intravitreal bevacizumab (Avastin) therapy for early and advanced neovascular age-related macular degeneration.
    Krebs I; Lie S; Stolba U; Zeiler F; Felke S; Binder S
    Acta Ophthalmol; 2009 Sep; 87(6):611-7. PubMed ID: 18937801
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Results of 1-year follow-up examinations after intravitreal bevacizumab administration for idiopathic choroidal neovascularization.
    Inoue M; Kadonosono K; Watanabe Y; Sato S; Kobayashi S; Yamane S; Ito R; Arakawa A
    Retina; 2010 May; 30(5):733-8. PubMed ID: 20168271
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration.
    Ahmadieh H; Taei R; Soheilian M; Riazi-Esfahani M; Karkhaneh R; Lashay A; Azarmina M; Dehghan MH; Moradian S
    BMC Ophthalmol; 2007 Jun; 7():10. PubMed ID: 17555600
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Visual improvement in central retinal vein occlusion (CRVO) following intravitreal injections of bevacizumab (Avastin(®) ).
    Algvere PV; Von Wendt G; Gudmundsson J; Seregard S; Kvanta A
    Acta Ophthalmol; 2010 Dec; 88(8):836-41. PubMed ID: 19900206
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Retinal pigment epithelial tears after intravitreal bevacizumab injection for neovascular age-related macular degeneration.
    Chan CK; Meyer CH; Gross JG; Abraham P; Nuthi AS; Kokame GT; Lin SG; Rauser ME; Kaiser PK
    Retina; 2007 Jun; 27(5):541-51. PubMed ID: 17558314
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: the second year of a prospective study.
    Bashshur ZF; Haddad ZA; Schakal AR; Jaafar RF; Saad A; Noureddin BN
    Am J Ophthalmol; 2009 Jul; 148(1):59-65.e1. PubMed ID: 19375689
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study.
    Bashshur ZF; Haddad ZA; Schakal A; Jaafar RF; Saab M; Noureddin BN
    Am J Ophthalmol; 2008 Feb; 145(2):249-256. PubMed ID: 18067876
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A study comparing two protocols of treatment with intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
    Arias L; Caminal JM; Casas L; Masuet C; Badia MB; Rubio M; Pujol O; Arruga J
    Br J Ophthalmol; 2008 Dec; 92(12):1636-41. PubMed ID: 18782803
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intravitreal bevacizumab therapy for neovascular age-related macular degeneration with large submacular hemorrhage.
    Stifter E; Michels S; Prager F; Georgopoulos M; Polak K; Hirn C; Schmidt-Erfurth U
    Am J Ophthalmol; 2007 Dec; 144(6):886-892. PubMed ID: 17916314
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.